Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

  1. Gebhart, G.
  2. Keyaerts, M.
  3. Guiot, T.
  4. Flamen, P.
  5. Ruiz-Borrego, M.
  6. Stradella, A.
  7. Bermejo, B.
  8. Escriva-de-Romani, S.
  9. Calvo Martínez, L.
  10. Ribelles, N.
  11. Fernandez-Abad, M.
  12. Albacar, C.
  13. Colleoni, M.
  14. Garrigos, L.
  15. Atienza de Frutos, M.
  16. Dalenc, F.
  17. Prat, A.
  18. Marmé, F.
  19. Schmid, P.
  20. Kerrou, K.
  21. Braga, S.
  22. Gener, P.
  23. Sampayo-Cordero, M.
  24. Cortés, J.
  25. Pérez-García, J.M.
  26. Llombart-Cussac, A.
  27. Show all authors +
Journal:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine

ISSN: 1535-5667

Year of publication: 2024

Volume: 65

Issue: 5

Pages: 708-713

Type: Article

DOI: 10.2967/JNUMED.123.266384 GOOGLE SCHOLAR lock_openOpen access editor
Data source: Scopus